ArticleNature communications2015
Two susceptibility loci identified for prostate cancer aggressiveness.
Registry-linked trialOpen access · goldAbstract read
In one paragraph
Article in Nature communications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01221168 (ProGene), which is not on this map. Cited by 61 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 1 pooled it
14.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ProGene: Etude Genetique et Epidemiologique du Cancer de la Prostate Familial
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 102 citations in OpenAlex.
- Prognostic Role of DNA Damage Response Genes Mutations and their Association With the Sensitivity of Olaparib in Prostate Cancer Patients.Cancer control : journal of the Moffitt Cancer CenterPooled it
- A prospective study of mitochondrial DNA copy number and the risk of prostate cancer.Cancer causes & control : CCC · 2017Trial
- Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance.Carcinogenesis · 2016Trial
- Polygenic risk score with KLK3 SNP-SNP interaction pairs for predicting prostate cancer aggressiveness.Communications medicine · 2026Article
- Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer.Cancer research · 2025Article
- Review
- Genetic Variants and Haplotype Structures in theHealth science reports · 2024Article
- Heterogeneous genetic architectures of prostate cancer susceptibility in sub-Saharan Africa.Nature genetics · 2024Article
- Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma.Cancer epidemiology · 2024Article
- Heterogeneous genetic architectures and evolutionary genomics of prostate cancer in Sub-Saharan Africa.Research square · 2023Article
- Article
- Prostate Cancer: Genetics, Epigenetics and the Need for Immunological Biomarkers.International journal of molecular sciences · 2023Review
- Article
- Article
- Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation.Nature genetics · 2022Article
- A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer.The Prostate · 2021Article
- Prostate cancer risk variants of the HOXB genetic locus.Scientific reports · 2021Article
- The oncological relevance of fragile sites in cancer.Communications biology · 2021Review
- Review
- Role of RASA1 in cancer: A review and update (Review).Oncology reports · 2020Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
50 authors at 20 institutions in 10 countries.
Sonja I BerndtDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA.
Zhaoming Wang1] Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA [2] Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21701, USA.
Meredith Yeager1] Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA [2] Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21701, USA.
Michael C AlavanjaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA.
Demetrius AlbanesDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA.
Laufey AmundadottirDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA.
Gerald AndrioleDivision of Urologic Surgery, Washington University School of Medicine, St Louis, Missouri 63110, USA.
Laura Beane FreemanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA.
Daniele CampaDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Geraldine Cancel-TassinCeRePP, Assistance Publique-Hôpitaux de Paris, UPMC University Paris 6, Paris, France.
Federico CanzianGenomic Epidemiology Group, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Jean-Nicolas CornuDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA.
Olivier CussenotCeRePP, Assistance Publique-Hôpitaux de Paris, UPMC University Paris 6, Paris, France.
W Ryan DiverEpidemiology Research Program, American Cancer Society, Atlanta, Georgia 30303, USA.
Susan M GapsturEpidemiology Research Program, American Cancer Society, Atlanta, Georgia 30303, USA.
Henrik GrönbergDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm 17177, Sweden.
Christopher A HaimanDepartment of Preventative Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA.
Brian HendersonDepartment of Preventative Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA.
Amy HutchinsonCancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21701, USA.
David J HunterDepartment of Epidemiology, Harvard School of Public Health, Boston, Massachusetts 02115, USA.
Timothy J KeyCancer Epidemiology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7BN, UK.
Suzanne KolbDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
Stella KoutrosDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA.
Peter KraftDepartment of Epidemiology, Harvard School of Public Health, Boston, Massachusetts 02115, USA.
Loic Le MarchandEpidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii 96813, USA.
Sara LindströmDepartment of Epidemiology, Harvard School of Public Health, Boston, Massachusetts 02115, USA.
Mitchell J MachielaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA.
Elaine A OstranderNational Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Elio RiboliDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College, London SW7 2AZ, UK.
Fred SchumacherDepartment of Preventative Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA.
Afshan SiddiqDepartment of Genomics of Common Disease, School of Public Health, Imperial College London, London SW7 2AZ, UK.
Janet L Stanford1] Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA [2] Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington 98195, USA.
Victoria L StevensEpidemiology Research Program, American Cancer Society, Atlanta, Georgia 30303, USA.
Ruth C TravisCancer Epidemiology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7BN, UK.
Konstantinos K TsilidisDepartment of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina 45110, Greece.
Jarmo VirtamoDepartment of Chronic Disease Prevention, National Institute for Health and Welfare, FI-00271 Helsinki, Finland.
Stephanie WeinsteinDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA.
Fredrik WilkundDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm 17177, Sweden.
Jianfeng XuCenter for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA.
S Lilly ZhengCenter for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA.
Kai YuDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA.
William WheelerInformation Management Services Inc., Rockville, Maryland 20852, USA.
Han ZhangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA.
African Ancestry Prostate Cancer GWAS Consortium
Joshua SampsonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA.
Amanda BlackDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA.
Kevin JacobsDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA.
Robert N HooverDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA.
Margaret TuckerDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA.
Stephen J ChanockDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA.
National Cancer Institute · USDivision of Cancer Epidemiology and GeneticsUniversity of Southern California · USHarvard University · USUniversity of Ghana · GHAmerican Cancer Society · USFred Hutch Cancer Center · USStony Brook University · USHeidelberg University · DEHenry Ford Hospital · USKarolinska Institutet · SEStanford University · USThe University of Texas MD Anderson Cancer Center · USUniversity of Oxford · GBVanderbilt University · USWake Forest University · USWestat (United States) · USAssistance Publique – Hôpitaux de Paris · FRCancer Center of Hawaii · USCleveland Clinic · US
Funding
Southern Community Cohort StudyR01CA092447 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BLOT, WILLIAM J., ZHENG, WEI · 2001 to 2015
$74.0MPLCO Trial Etiologic and Early Marker StudyZIACP010152 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MOORE, STEVEN · 2009 to 2025
$29.9MFinding Genes for Human Prostate CancerZIAHG200325 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI OSTRANDER, ELAINE · 2009 to 2021
$17.7MBreast Cancer Family Registry CohortUM1CA164920 · NCI · CANCER PREVENTION INSTIT OF CALIFORNIA · PI ANDRULIS, IRENE, BUYS, SAUNDRA S · 2012 to 2017
$12.7MGENE-ENVIRONMENT INTERACTION IN PROSTATE CANCERR01ES011126 · NIEHS · HENRY FORD HEALTH SYSTEM · PI RYBICKI, BENJAMIN A. · 2000 to 2017
$8.0MPCPT and SELECT cohorts: Core Infrastructure Support for Cancer Research UM1CA182883 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI TANGEN, CATHERINE M., THOMPSON, IAN M. · 2013 to 2017
$5.2MSTUDIES OF OCCUPATIONAL CANCER--PESTICIDESZ01CP010119 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ALAVANJA, MICHAEL · 1996 to 2008
$5.0MHEALTH EFFECTS OF EXPOSURES IN AGRICULTUREZ01ES049030 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI SANDLER, DALE P · 1997 to 2008
$889kCancer Research UK 16491Cancer Research UK 19170Intramural NIH HHS Z01 CP010119Intramural NIH HHS Z01 ES049030Intramural NIH HHS ZIA CP010152NCI NIH HHS R01 CA092447NCI NIH HHS UM1 CA164920NCI NIH HHS UM1 CA182883NCI NIH HHS Z01-CP010119NCI NIH HHS ZIA-CP010152-11NIEHS NIH HHS R01 ES011126
Abstract
Most men diagnosed with prostate cancer will experience indolent disease; hence, discovering genetic variants that distinguish aggressive from nonaggressive prostate cancer is of critical clinical importance for disease prevention and treatment. In a multistage, case-only genome-wide association study of 12,518 prostate cancer cases, we identify two loci associated with Gleason score, a pathological measure of disease aggressiveness: rs35148638 at 5q14.3 (RASA1, P=6.49 × 10(-9)) and rs78943174 at 3q26.31 (NAALADL2, P=4.18 × 10(-8)). In a stratified case-control analysis, the SNP at 5q14.3 appears specific for aggressive prostate cancer (P=8.85 × 10(-5)) with no association for nonaggressive prostate cancer compared with controls (P=0.57). The proximity of these loci to genes involved in vascular disease suggests potential biological mechanisms worthy of further investigation.
Indexed as
Genetic LociGenetic Predisposition to DiseaseCase-Control StudiesHumansMaleNeoplasm GradingNeoplasm InvasivenessProstatic Neoplasms
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT01221168ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.